FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894953910> ?p ?o ?g. }

• W2894953910 endingPage "94" @default.
• W2894953910 startingPage "84" @default.
• W2894953910 abstract "Prostate cancer (PC) is the most common disease in men over age 50, and its prevalence rate has been gradually increasing since 1980. Taxane-derived anticancer agents are the primary agents used to treat metastatic prostate cancer patients; however, the side effects and acquired drug resistance limit the success of these therapies. Because there is no specific treatment for paclitaxel-resistant prostate cancer, it is necessary to develop new targets and therapeutic strategies to overcome the acquired resistance. In this study, the antitumor activity of a novel selenonucleoside (4'-selenofuranosyl-2,6-dichloropurine, LJ-2618), a third-generation nucleoside, and its plausible mechanisms of action in paclitaxel-resistant prostate cancer (PC-3-Pa) cells were investigated. The established PC-3-Pa cells exhibited over 100-fold resistance against paclitaxel compared to the paclitaxel-sensitive PC-3 cells. LJ-2618, however, effectively inhibited the proliferation of both cell lines with similar IC50 values in vitro. In PC-3-Pa cells, the activated PI3K/Akt signaling pathway was suppressed by LJ-2618 treatment. In addition, Skp2 was found to be over-expressed in paclitaxel-resistant cells, and the transfection of Skp2 siRNA recovered the sensitivity of paclitaxel in PC-3-Pa cells. Furthermore, LJ-2618 significantly down-regulated Skp2 expression in PC-3-Pa cells by promoting degradation and inducing destabilization of Skp2, which triggers G2/M cell cycle arrest. In a xenograft mouse model implanted with PC-3-Pa cells, LJ-2618 (3 or 10 mg/kg) effectively inhibited tumor growth with the enhancement of Skp2 degradation and induction of p27 expression in tumor tissues. These findings suggest that LJ-2618 may have potential for overcoming paclitaxel resistance via promoting Skp2 degradation and stabilizing p27 expression in PC-3-Pa cells. Therefore, the novel selenonucleoside LJ-2618 may lead to the development of a new treatment strategy for patients with paclitaxel-resistant, castration-resistant prostate cancer." @default.
• W2894953910 created "2018-10-12" @default.
• W2894953910 creator A5011790236 @default.
• W2894953910 creator A5033086793 @default.
• W2894953910 creator A5039708869 @default.
• W2894953910 creator A5059646032 @default.
• W2894953910 creator A5065567466 @default.
• W2894953910 creator A5072755306 @default.
• W2894953910 creator A5089594601 @default.
• W2894953910 creator A5091279086 @default.
• W2894953910 date "2018-12-01" @default.
• W2894953910 modified "2023-09-24" @default.
• W2894953910 title "A novel selenonucleoside suppresses tumor growth by targeting Skp2 degradation in paclitaxel-resistant prostate cancer" @default.
• W2894953910 cites W1965239527 @default.
• W2894953910 cites W1966622127 @default.
• W2894953910 cites W1981711832 @default.
• W2894953910 cites W1999459611 @default.
• W2894953910 cites W2005868921 @default.
• W2894953910 cites W2006771504 @default.
• W2894953910 cites W2022632543 @default.
• W2894953910 cites W2029304297 @default.
• W2894953910 cites W2030894954 @default.
• W2894953910 cites W2030981986 @default.
• W2894953910 cites W2056164539 @default.
• W2894953910 cites W2065919583 @default.
• W2894953910 cites W2080921790 @default.
• W2894953910 cites W2083450231 @default.
• W2894953910 cites W2087667264 @default.
• W2894953910 cites W2091954153 @default.
• W2894953910 cites W2095558022 @default.
• W2894953910 cites W2097348057 @default.
• W2894953910 cites W2098817749 @default.
• W2894953910 cites W2102071794 @default.
• W2894953910 cites W2102653231 @default.
• W2894953910 cites W2107436374 @default.
• W2894953910 cites W2111212562 @default.
• W2894953910 cites W2112451226 @default.
• W2894953910 cites W2142501479 @default.
• W2894953910 cites W2151860429 @default.
• W2894953910 cites W2165688410 @default.
• W2894953910 cites W2211072972 @default.
• W2894953910 cites W2235523093 @default.
• W2894953910 cites W2381855049 @default.
• W2894953910 cites W2527239283 @default.
• W2894953910 cites W2745413515 @default.
• W2894953910 cites W2790240293 @default.
• W2894953910 cites W2952496828 @default.
• W2894953910 cites W4293247451 @default.
• W2894953910 cites W4301651270 @default.
• W2894953910 doi "https://doi.org/10.1016/j.bcp.2018.10.002" @default.
• W2894953910 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30292755" @default.
• W2894953910 hasPublicationYear "2018" @default.
• W2894953910 type Work @default.
• W2894953910 sameAs 2894953910 @default.
• W2894953910 citedByCount "32" @default.
• W2894953910 countsByYear W28949539102019 @default.
• W2894953910 countsByYear W28949539102020 @default.
• W2894953910 countsByYear W28949539102021 @default.
• W2894953910 countsByYear W28949539102022 @default.
• W2894953910 countsByYear W28949539102023 @default.
• W2894953910 crossrefType "journal-article" @default.
• W2894953910 hasAuthorship W2894953910A5011790236 @default.
• W2894953910 hasAuthorship W2894953910A5033086793 @default.
• W2894953910 hasAuthorship W2894953910A5039708869 @default.
• W2894953910 hasAuthorship W2894953910A5059646032 @default.
• W2894953910 hasAuthorship W2894953910A5065567466 @default.
• W2894953910 hasAuthorship W2894953910A5072755306 @default.
• W2894953910 hasAuthorship W2894953910A5089594601 @default.
• W2894953910 hasAuthorship W2894953910A5091279086 @default.
• W2894953910 hasConcept C104317684 @default.
• W2894953910 hasConcept C121608353 @default.
• W2894953910 hasConcept C126322002 @default.
• W2894953910 hasConcept C134459356 @default.
• W2894953910 hasConcept C185592680 @default.
• W2894953910 hasConcept C190283241 @default.
• W2894953910 hasConcept C25602115 @default.
• W2894953910 hasConcept C2776787872 @default.
• W2894953910 hasConcept C2777292972 @default.
• W2894953910 hasConcept C2777511904 @default.
• W2894953910 hasConcept C2780192828 @default.
• W2894953910 hasConcept C29537977 @default.
• W2894953910 hasConcept C502942594 @default.
• W2894953910 hasConcept C530470458 @default.
• W2894953910 hasConcept C55493867 @default.
• W2894953910 hasConcept C62112901 @default.
• W2894953910 hasConcept C71924100 @default.
• W2894953910 hasConcept C75217442 @default.
• W2894953910 hasConcept C86554907 @default.
• W2894953910 hasConcept C96232424 @default.
• W2894953910 hasConcept C98274493 @default.
• W2894953910 hasConceptScore W2894953910C104317684 @default.
• W2894953910 hasConceptScore W2894953910C121608353 @default.
• W2894953910 hasConceptScore W2894953910C126322002 @default.
• W2894953910 hasConceptScore W2894953910C134459356 @default.
• W2894953910 hasConceptScore W2894953910C185592680 @default.
• W2894953910 hasConceptScore W2894953910C190283241 @default.
• W2894953910 hasConceptScore W2894953910C25602115 @default.
• W2894953910 hasConceptScore W2894953910C2776787872 @default.

• next